| Name | Title | Contact Details |
|---|
C2N Diagnostics is a privately-held biotechnology company based in St. Louis, Missouri. We focus on the development of clinical diagnostics and therapeutics for serious brain disorders, with a particular emphasis on Alzheimer`s disease and related forms of progressive neurodegeneration.
Lumos Diagnostics delivers custom diagnostic solutions by combining deep market insight with existing platform technologies, assay development capability and regulated manufacturing experience.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.
Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.
miRagen Therapeutics is a biotechnology company advancing new treatments for patients with diseases that are underserved by today’s therapies.